The Many Works of Eric Lefkofsky

Eric Lefkofsky is an entrepreneur born on September 2, 1969. He is the founder of several well-known companies, such as Groupon, Echo Global Logistics, InnerWorkings, Mediaocean, Uptake, and Tempus. Eric was raised in Southfield, Michigan. Graduating with honors from the University of Michigan, he went on to earn his Juris Doctor Degree from the University of Michigan Law School.Lefkofsky is the founder and CEO of Tempus, a startup research company dedicated to finding a cure for cancer. Tempus works out of Lightbank, which is a company also founded by Eric Lefkofsky. They assist doctors with treatment decisions by “analyzing a patient’s genetic code in the context of molecular therapies”. They strive to help doctors have a better understanding of each patient’s individual case.

Currently, Tempus works with patients diagnosed with breast, pancreatic and lung cancers, but plans to expand its research to include more types of cancer. They are dedicated to helping doctors plan a better method of treatment for each patient.Eric Lefkofsky is the author of a book titled Accelerated Disruption. The book states that “Accelerated Disruption is business development moving at the speed of the next technological advancement.” It stresses how technology will thrive and affect businesses in coming years. Some of the concepts that the book addresses, according to the official website, are as follows:

* Choosing the right industries to innovate

* Understanding the concept of pain in an industry

* Getting the best out of your people through smart automation

Throughout the book, it is discussed how disruptive businesses are formed. It teaches up and coming entrepreneurs to make their dreams a reality.

In 2006, the Lefkofsky Family Foundation was formed by Eric and his wife. They strive to enhance the quality of life for communities by providing quality education, medical research and more. The foundation funds mostly in Chicago, and they also support some popular organizations. Many Chicago nonprofit organizations have gotten involved.


Clay Siegall Believes In Interacting With Smart People

Clay B. Siegall is the co-founder of Seattle Genetics. He founded the company in 1998. Currently, he is serving as the President, Chief Executive Officer and the Chairman of its Board.


Clay Siegall is basically a scientist. He is more focused on those cancer therapies which are targeted. Hence he built Seattle Genetics. This is based on a lot of research along with scientific innovation. His passion lies in helping the patients suffering from cancer.


He has been instrumental in developing several antibody-drug conjugates. It was in 2011 that he managed to secure FDA approval for the first ADC product that was developed by his company. This was for ADCETRIS® (brentuximab vedotin). It is a globally recognized brand today. This product has already been approved in nearly 65 countries.


Clay Siegall has also served with the Bristol-Myers Squibb Pharmaceutical Research Institute. This was from 1991 to 1997. He has worked with the National Cancer Institute, National Institutes of Health from 1988 to 1991. He was on the Boards of Directors of Ultragenyx Pharmaceutical, and Alder BioPharmaceuticals besides Washington Roundtable.


Clay Siegall is the author of over 70 publications. He is holding 15 patents too. He has earned his Ph.D. in Genetics from the George Washington University. He has a B.S. in Zoology from the University of Maryland.


He has launched Seattle Genetics as he wanted to help patients suffering from cancer. He knew of the limited tools available to oncologists. He had seen how his father had progressed with his cancer. This is why he was keen to improve upon these tools. Hence he went on to earn his doctorate in genetics. Then Clay joined Bristol-Myers Squibb in their Pharmaceutical Research Institute. All this experience helped him to prepare to run a company. So he founded Seattle Genetics


Clay Siegall likes to interact with smart people. He feels that they have expertise in their area. Hence a lot can be learned from them. Besides, they are the ones who can turn ideas into reality. This is why he is consciously recruiting smart people in his company and feeling the difference.

Eric Lefkofsky, The Man Behind Groupon is Focusing on Big Data to Propel His New Venture to Success

Through the exploitation of big data, a Chicago-based startup is keen on championing personalized cancer therapies. Currently, personalized health care in the fight against cancer is a preserve for the wealthy individuals because it involves sequencing of a person’s genome. The startup aims at leveraging the power of technology, specifically machine learning and data collected from patients who’ve battled cancer to create the new age treatments.

The startup is called Tempus. It was created by two entrepreneurs, Mr Eric Lefkofsky and Brad Keywell.

The company is a first in the collection of big data for cancer patients. It was built on the premise of availing big data for decision making in the fight against cancer. Tempus has based its main offices in Chicago.

Recently, the firm made a major pronouncement. It has entered into a partnership with the University of Chicago to provide genome sequencing and analysis of close to 1,000 breast cancer patients to the University. The breast cancer experts at the institution’s Department of Oncology will then use the data to come up with tailored treatment plans for patients. This approach to cancer treatment is hinged on the fact that different factors such as genetic makeup affect the response of a patient to treatment.

Big data is the basis upon which modern day professionals make decisions. In the long term, the data collected by Tempus will help guide doctors on how they can achieve effective treatment and better patient outcomes. Click here to know more.

Currently, oncologists make treatment decisions based on the limited knowledge they have learned. With big data, doctors will have more detailed and genetic-specific information that could help them make better decisions when administering therapies.

The irony of cancer treatment is that in as much as there are over 1.7 million new cases of cancer that are reported in the US yearly, the public healthcare has data for only 20,000 patients. To achieve the concept of personalized healthcare in the fight against cancer succeeds more resources have to be devoted towards collection and analysis of this data.

The founder of Tempus, Eric Lefkofsky is also the brainchild of acclaimed brands such Groupon, Lightbank, Drivin and Mediabank.


Omar Boraie Supports Important Research

A recent NewsWise article  highlights the crucial work being done at Rutgers University in precision medicine and mentions that an endowed chair was created in the name of supporter Omar Boraie at the Rutgers Cancer Institute to continue doing important research into cancers and their causes. Mr. Boraie, a developer in New Brunswick, recently made a generous donation of 1.5 million dollars to help fund the work being done at the Cancer Institute, and according to, the Omar Boraie Chair in Genomic Science will ensure that groundbreaking research currently being done at Rutgers will continue.

Omar Boraie has studied chemistry himself and has long been interested in developments in cancer treatments. The director of the cancer institute at Rutgers has praised his generosity.

Specifically, the endowed chair will help fund research in genomics. Researchers at Rutgers are developing ways to create treatments for cancer at the genetic level, allowing them to customize approaches for individual patients. Rutgers is at the very cutting edge of using precision medicine and genomics to treat cancer, and researchers at the university are pioneering ways of attacking extremely rare forms of cancer that do not respond to conventional therapies.

The endowed chair has been named to Shridar Ganesan, MD, PhD, one of the leading scientists at the Cancer Institute. The research of Dr. Ganesan extends from the idea that cancer is not a single disease but rather a collection of diseases that require individualized treatments. He has made substantial progress at isolating and defining individual strains of the disease, and this has given hope to both scientists searching for cures and patients suffering from rare cancers.

The Rutgers Cancer Institute works closely with hospitals all over New Jersey to gather data, do research, conduct clinical tests and develop treatments. In short, Omar Boraie’s assistance to its mission has the potential to do a tremendous amount of good.